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heart disease (prior myocardial infarction, 22.9% vs 44.2%, p<0.001), and more history
of hypertension (79.2% vs 55.1%, p<0.001). Slightly higher resting heart rates and blood
pressures were also observed in Blacks. While the reported HF etiology was predomi-
nantly hypertensive in Blacks and ischemic in Whites, the proportion of patients with pre-
served left ventricular function did not differ between the two groups, as 16.5% of Whites
and 16.7% of Blacks had left ventricular ejection fractions >40% (p=0.93). Physician
assessment of carvedilol titration demonstrated excellent tolerability in both groups, with
no problem or mildly difficult assessments recorded for 86.2% of Black patients vs 81.8%
of White patients, p=0.02. There was no difference in distribution of carvedilol dose by
race, with most patients achieving a dose of at least 6.25 mg bid. Compared to the 12
months prior to carvedilol initiation, hospitalization rates for all-causes, cardiovascular
reasons other than HF, and HF were reduced in both groups during carvedilol treatment.
The incidence of death per 1,000 person-years was similar in Blacks (71.0) and Whites
(73.6), and the hazard ratio was 1.01 (95% CI 0.68 to 1.49; p=0.96).
Conclusions: In the community setting of COHERE, carvedilol was well tolerated in
Blacks who, despite different baseline characteristics and risk factors for HF, also demon-
strated safety and efficacy comparable to that seen in White patients.
1172-71 Practical Predictors of Clinical Outcomes in Patients 
Initiating Beta-Blockers for Heart Failure: Findings of a 
Community-Based Registry
Barry Greenberg, Sandra R. Lottes, Jeanenne J. Nelson, Mary Ann Lukas, Michael B. 
Fowler, Barry M. Massie, William T. Abraham, Edward M. Gilbert, Joseph A. Franciosa, 
and the COHERE Participant Physicians, GlaxoSmithKline Pharmaceuticals, 
Philadelphia, PA
Background: Increased morbidity and mortality in heart failure (HF) patients has been
related to risk factors derived from populations in clinical trials, at hospital discharge, or in
localized geographic/socioeconomic strata, and were identified before wide use of beta-
blockers for HF.
Methods: The Coreg Heart Failure Registry (COHERE) observed 4,280 unselected HF
patients during 1-yr follow-up after initiating carvedilol in a community setting. Patients
entered the registry regardless of ejection fraction (EF). Significant risk factors for the
composite of death, hospitalization for HF and hospitalization for cardiovascular (CV)
reasons other than HF were identified by age-, sex-, and race-adjusted analyses. Inde-
pendent risk factors were identified from a multivariable analysis adjusted for all factors
simultaneously.
Results: Over this period 7% of patients died, 11% were hospitalized for HF, 12% were
hospitalized for other CV reasons, and 27% had any of these events. Key findings of the
multivariate analysis are shown in the table. 
Although EF and blood pressure were significant predictors when adjusted for age, sex,
and race, the relationship did not persist when simultaneously adjusted for other co-vari-
ables.
Conclusions: Simple historical information identifies community HF patients at
increased risk for death or hospitalization in the year after initiating carvedilol. In this pop-
ulation not selected by EF, these historical factors appear to better predict risk than did
EF.
1172-72 Combination Evidence-Based Therapy Improves 
Survival After Percutaneous Coronary Intervention
Brahmajee K. Nallamothu, Debabrata Mukherjee, Stanley Chetcuti, Paul M. Grossman, 
Rupal Dumasia, Eva Kline-Rogers, Bertram Pitt, Kim A. Eagle, Mauro Moscucci, 
University of Michigan, Ann Arbor, MI
Introduction: The impact of combination "evidence-based" therapy (ASA, beta-blockers,
ace inhibitors, and statin use) on long-term survival of patients undergoing percutaneous
coronary intervention (PCI) is uncertain.
Hypothesis: We hypothesized that post-PCI patients with higher rates of use of evi-
dence-based therapy would have lower mortality rates.
Methods: We collected clinical and angiographic data on consecutive PCIs from July
1997 to October 2001. An additive evidence-based therapy score (0-4) was calculated by
applying 1 point each to hospital discharge on ASA, beta-blockers, ace inhibitors and
statins. Follow-up long-term survival was obtained by telephone contact and/or searching
the Social Security Death Index. Using a Cox proportional hazards model, we assessed
the impact of the score on survival after adjusting for age, sex, cardiac risk factors (e.g.,
diabetes(DM), hypertension, congestive heart failure, ejection fraction, extent of coronary
disease, renal insufficiency, hx of bypass surgery/PCI/acute myocardial infarction(MI),
clinical priority and procedural factors (e.g., stent, gIIb/IIIa use).
Results: 2311 patients underwent 3231 PCIs with a mean-follow-up of 344 +/- 225 days.
Mean age was 63 +/- 12 years; 752 (33%) were women, 609 (26%) had DM, 487 (19%)
had recent MI. Most (78%) received stents. 211 (9%) patients were discharged on 0-1
evidence-based therapies (i.e., score of 0-1) and 570 (25%) were discharged on all 4 evi-
dence-based therapies. After multivariate adjustment, the evidence-based therapy score
remained an independent predictor of improved survival (HR per 1 unit increase in evi-
dence-based therapy score, 0.78; 95% ci, 0.66-0.92; p=0.003). Other significant factors
included: advanced age, congestive heart failure, ejection fraction, left main disease,
multivessel PCI, renal insufficiency, and post-PCI QWMI.
Conclusion: The use of combination evidence-based therapy as assessed by an addi-
tive score is independently associated with improved survival after PCI. Evidence-based
therapy use should be strongly encouraged and implemented in these patients.
1172-73 First Postoperative Day Prognosis Score in Patients 
Undergoing Cardiac Surgery Based on Pre-, Peri-, and 
Postoperative Variables
Renato V. Gomes, Alexandre Rouge, Fernando Aranha, Marco A. Fernandes, Pedro 
Nogueira, Jorge Sabino, Luiz A. Campos, Bernardo Tura, Hans F. Dohmann, Hans J. 
Dohmann, Hospital Pro-cardiaco, Rio de Janeiro, Brazil, Instituto nacional de Cardiologia 
de Laranjeiras, Rio de Janeiro, Brazil
Background: We have several prognosis models for heart surgery (HS). However, these
scores were based on preoperative variables, our model have used both, preoperative
and first postoperative day (FPOD) . Objectives: To create a predictive score of in-hospi-
tal mortality in patients (pts) undergoing HS and admitted to a public and private surgical
intensive care unit (SICU), analyzing pre-, perioperative and FPOD variables. Case
series and methods: Classical cohort of data (1,458 pts) consecutively collected from
June 2000 to February 2003. All 46 variables were previously defined according to the
major prognostic index found in the literature. The statistical analysis comprised: univari-
ate analysis with the chi-square test, Student t test, Mann-Whitney and Pearson tests, fol-
lowed by logistic regression and stepwise (likelihood ratio), with the linear trend test and
ROC curve. Results: The score , shown in the attached table, provides the following risk
prediction: 0 to 4 – low risk; 5 to 9 – medium; and 10 to 14 – high. The results had signif-
icance (p<0.0001) and linear trend (p<0,0001). The area under the ROC curve was 0.84.
Conclusions: The score shows the strength of the variables on the FPOD, such as worse
PO2/ FiO2 < 100, epinephrine > 0,1 or norepinephrine > 0,1, and mechanical ventilation
duration > 12 h, probably related to perioperative factors, such as type of anesthesia,
host response, hemodynamic profile, use or nonuse of corticosteroids.
1172-74 Pulmonary Hypertension Is Strongly Associated With 
Mortality in Sickle Cell Disease: Comparison of 
Echocardiographic Outcome Predictors
Yukitaka Shizukuda, Vandana Sachdev, Inez Ernst, James S. Nichols, Maria Jison, 
Bernice Brown, William Blackwelder, Griffin P. Rodgers, Oswaldo Castro, Frederick P. 
Ognibene, Jonathan P. Plehn, Mark T. Gladwin, National Heart, Lung, and Blood 
Institute, Bethesda, MD, Howard University, Washington, DC, DC
Background: The development of pulmonary hypertension (PH) has been reported in
most hemolytic anemias and preliminary reports have suggested its prognostic value in






NYHA class (IV vs I) 3.56 2.23 - 5.68 <0.001
NYHA class (III vs I) 2.85 2.08 - 3.91 <0.001
HF Hospitalization prior yr 1.92 1.63 - 2.25 <0.001
NYHA class (II vs I) 1.66 1.22 - 2.26 <0.001
History of angina 1.38 1.17 - 1.63 <0.001
HF duration (> 2yr vs < 6 mos) 1.28 1.06 - 1.54 0.009
History of diabetes 1.22 1.04 - 1.43 0.013
History of acute MI 1.20 1.01 - 1.43 0.039
MD (non-cardiologist vs cardiologist) 1.12 0.94 - 1.33 0.216
Sex (males vs females) 1.05 0.89 - 1.23 0.555
Age ( per 1 yr increase) 1.01 1.00 - 1.01 0.171
Race (Black vs Caucasian) 1.00 0.78 - 1.28 0.992
MD (yrs since graduation 19-24 vs <13 yr) 0.82 0.68 - 1.00 0.055
MD (yrs since graduation 13-18 vs <13 yr) 0.76 0.62 - 0.94 0.011
Insurance (commercial vs Medicare/Medicaid) 0.76 0.60 - 0.95 0.017
MD (yrs since graduation >24 vs <13 yr) 0.71 0.58 - 0.87 <0.001
HF cause (Idiopathic vs CAD) 0.71 0.55 - 0.91 0.007
HF cause (HTN vs CAD) 0.69 0.53 - 0.89 0.004
CAD = coronary artery disease; HTN = hypertension
95% CI for OR
Characteristics OR Lower Upper Score
Age 64 to 74years 2,05 1,16 3,63 +1
Age >75 years 4.79 2,60 8,83 +2
Left atrium>45mm 2,58 1,53 4,37 +1
Creatinine>2mg/dl 4,84 1,87 12,48 +2
Extracorporeal circulation>180min 4,93 1,99 12,18 +2
Worse FPOD PO2/FiO2 < 100 9,47 3,18 28,23 +3
FPOD Epinephrine > 0.1 or Nor > 0.1 mcg/kg/min 6,78 3,99 11,53 +3
FPOD duration of mechanical ventilation > 12 h 2,24 1,34 3,72 +1








echocardiographic estimation of pulmonary artery pressure and other echocarciographic
and clinical features in 175 consecutive adult SSD patients (74 male, 101 female, mean
age = 37 ± 11 years) recruited from a local hospital and community clinics who were fol-
lowed for a median period of 12 months.
Methods: PH was prospectively defined as a tricuspid regurgitation jet velocity of > 2.5 m/
sec. 2-Dimensional assessment of chamber dimensions and ventricular systolic perfor-
mance, pulsed Doppler quantitation of left ventricular stroke volume, continuous wave
Doppler estimation of pulmonary artery systolic pressure, and right ventricular systolic
and diastolic function (dP/dt from TR spectral trace) were examined.
Results. PH was present in 33 % of patients and peak TR velocities (TRV) > 3 m/sec
were observed in 9%. In univariate analysis, TRV was the strongest predictor of all-cause
mortality (relative risk 8.3; 95% CI = 1.7 to 40; P = 0.003). TRV did not correlate with left
ventricular ejection fraction, stroke volume or cardiac output. Patients with TRV > 2.5 m/
sec had significantly larger right atrial areas (20 ± 5 vs 18± 4 cm2, P < 0.001, values are
mean + SD) and evidence of right ventricular systolic and diastolic dysfunction (+dP/dt;
419 ± 139 vs 659 ± 371 mmHg/sec, P < 0.01 and –dP/dt; 157 ± 52 vs 236 ± 77 mmHg/
sec, P < 0.001). Ventricular volumes, ejection fraction, and severity of mitral regurgitation
were similar between groups as were non-echo SSD parameters including fetal hemoglo-
bin, white blood cell and platelet counts, and hydroxyurea use.
Conclusion: Secondary pulmonary hypertension is a powerful independent predictor of
mortality in SSD, is unrelated to cardiac output and is associated with abnormalities in
RV systolic and diastolic function. Echocardiography can be used as a screening tool to
identify a high risk subgroup in SSD that may benefit from therapeutic interventions.
1172-75 Cost-Effectiveness of Screening Coronary Artery 
Disease Patients With B-Type Natriuretic Peptide
Paul A. Heidenreich, Kirsten Bibbins-Domingo, Michael X. Pham, Mary A. Whooley, VA 
Palo Alto Health Care System, Palo Alto, CA, VA San Francisco Health Care System, 
Palo Alto, CA
Purpose: We sought to determine the cost-effectiveness of screening coronary artery
disease (CAD) patients with B-type natriuretic peptide (BNP) to identify those with low left
ventricular ejection fraction (EF).
Methods: We constructed a decision tree that compared screening with BNP with follow-
up echocardiography (echo) in those with a high BNP to no screening. We estimated
economic and health outcomes using a Markov-model based on data from the SOLVD
treatment and prevention trials. We determined the sensitivity (67%) and specificity
(78%) of BNP (Biosite, threshold 100 pg/ml) for the detection of an EF < 40% using data
from 293 patients with coronary artery disease and no history of heart failure.
Results: The population for the base case had mean age of 69 years and 92% were
male. The prevalence of EF below 40% was 3.1%. Screening 1000 CAD patients with
BNP followed by echo in those with a BNP > 100 pg/dl increased the cost of care by
$216,000, and improved outcome by 7.2 quality adjusted life years ($30,000/QALY).
Screening with echo in all patients provided greater outcome compared to first testing
with BNP (3.3 QALYs) but cost an additional $445,000 ($135,000/QALY). The cost-effec-
tiveness of screening was most sensitive to the prevalence of low ejection fraction (Fig-
ure). If the prevalence is over 1.5%, screening increases outcome at a cost less than
$50,000/QALY gained.
Conclusion: Screening men with CAD for low EF with BNP improves outcome at a cost
that is less than other accepted medical treatments.
1172-76 Healthcare Costs for Cardiovascular Disease in Women 
With and Without Obstructive Coronary Disease: 
Results From the National Institutes of Health-National 
Heart, Lung, and Blood Institutes-Sponsored Women's 
Ischemia Syndrome Evaluation (WISE)
Leslee J. Shaw, Barry L. Sharaf, B. Delia Johnson, George Sopko, Carl J. Pepine, Gerry 
Pohost, Steve Reis, William Rogers, Sheryl F. Kelsey, C. Noel Bairey Merz, The WISE 
Study Group, Atlanta Cardiovascular Research Institute, Atlanta, GA
Coronary angiography (Angio) is a frequently performed procedure in women, with non-
obstructive (<50% stenosis ) coronary disease (CAD) often noted.
We examined CAD prognosis and costs in 887 women undergoing Angio. Events, hospi-
talizations, and drug use was recorded during annual visits. Costs were discounted (5%/
year [yr]), inflated (yr 2002), projected through lifetime, and compared using general lin-
ear models (adjusted for race, income, marital status, and insurance).
Of the 887 women, 62%, 17%, 11%, and 10% had <50% stenosis, and 1, 2, and 3 vessel
CAD. During 4-yrs of follow-up, 44 deaths, 18 MIs, and 155 angina hospitalizations were
observed. In a risk-adjusted Cox model (adjusted for risk factors and symptoms), annual
death or MI rates were 0.9% for women with <50% stenosis versus (vs) 2.3%-6.0% for
those with 1-3 vessel CAD (p=0.001). Angina hospitalization rates were 14% and 25% for
women with < vs >50% stenosis (p=0.03). After yr 1, repeat Angio or angina hospitaliza-
tion was 1.8-fold higher in women with <50% stenosis vs 1 vessel CAD women
(p<0.0001). 4-yr mean±standard deviation costs (x $1,000) ranged from $13±$16 to
$27±$25 for 0 to 3 vessel CAD (p<0.0001). Due to a younger age at Angio, lifetime costs
were $206,246 for women with <50% stenosis increasing to $540,136 for those with 3
vessel CAD (Figure).
In conclusion, symptom-driven care for women is costly even in the absence of obstruc-
tive CAD. The societal economic burden for CAD care in women with angina could range
from $244-$966 billion dollars.
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853-1 The Use of Medical Simulators as Part of a 
Comprehensive Interventional Cardiology Teaching 
Course
Ross Prpic, William Lewandowski, Brett Sasseen, Jeffrey Popma, Harvard Clinical 
Research Institute, Boston, MA
Background: The purpose of this pilot study was to examine the use of simulation as a
tool for teaching coronary angiography and angioplasty techniques to Fellows in the Peo-
ples Republic of China.
Methods: The angiography and angioplasty simulator was designed and developed
using a systematic approach. First, a detailed description of 10 different clinical cases
were developed and reviewed for content and accuracy by several experienced Interven-
tional Cardiologists. Each Procedure Description was then broken down into the finite
constituent tasks a Cardiologist must perform in order to successfully perform angiogra-
phy and angioplasty. The tasks were then analyzed to ascertain their performance
domain (cognitive, psychomotor) with particular emphasis on those aspects of perfor-
mance which are prone to error. This Task Analysis was then reviewed by Interventional
Cardiologists, revised, and became the metric for the development of the simulator. In
November 2002, six simulators were used as part of a 5 day seminar for 23 Cardiology
Fellows in Beijing, and again in February 2003. Experienced Cardiologists from the
United States and China served as faculty. The seminars consisted of didactic lectures
followed by practice and feedback sessions on the simulators. At the end of each day stu-
dent progress and performance was reviewed by Faculty. In addition, the candidates
completed seminar evaluation forms.
Results: The faculty members felt that the simulation content was valid, in that it suffi-
ciently replicated interventional procedures to provide useful and valuable training. Sub-
jectively, the system was able to quickly discriminate between master and novice
performers. Candidates demonstrated substantial improvement in the performance of
targeted tasks, particularly in the areas of refining angiographic views and interventional
tool manipulation.
Conclusion: This pilot study demonstrated that simulation, when properly designed and
integrated into a curriculum, is accepted by Cardiologists as a training tool, and that it has
the propensity to markedly improve the performance of Fellows. Follow-on formal studies
are planned to document concurrent and predictive validity.
